🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to health experts.

An International Health Concern

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting in excess of 82 million infections annually. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The WHO has designated it as a "critical concern". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts anticipate that specific application of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This treatment, which is employed against urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This milestone represents a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Outcomes and Global Access

Based on findings detailed in a prominent scientific publication, the new drug cured more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines two antibiotics. The trial enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Doctors on the front lines have expressed optimism. Access to a easy-to-administer therapy such as this is described as a "game-changer" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for patients and to prevent the spread of extremely resistant gonorrhoea around the world.